We’re excited to announce that Nymbl Science has been selected as a finalist in the GSMA’s 2020 Global Mobile (GLOMO) Awards, the premier global competition for mobile technology and solutions, for Best Mobile Innovation for Health and Biotech! Other finalists in this category include Samsung, Ericsson, and Vimplecom.

The GLOMO Awards celebrate key innovations and achievements from across the mobile industry each year. They are a part of GSMA’s Mobile World Congress, the world’s largest annual conference on all things mobile (with over 100,000 attendees each year in Barcelona).

The GLOMO Awards judging panel is comprised of more than 300 leading industry and subject matter experts, analysts, journalists, academics, and mobile operator representatives from across the world. According to the GSMA, the Best Mobile Innovation for Health and Biotech award recognizes:

“the broad range of innovation and advances in the growth and development of mobile connectivity to support the healthcare eco-system. This includes all aspects of mobile medical healthcare products, services, solutions and applications that are emerging today, from de-centralised access to health services and remote diagnosis solutions, chronic disease management and healthcare monitoring to treatment compliance health coaching as well as everyday lifestyle apps for well-being and fitness.”

We are honored to be recognized as a pioneer in the mobile world, and to be included in this list of finalists which are globally recognized mobile companies. This prominent nomination validates our approach to solving one of today’s biggest healthcare challenges.